Clinical trials: in Nigeria
Hypertension, Diabetes
Genetics of Type 2 Diabetes in West Africans
Background: Type 2 diabetes (T2D) and associated complications are major contributors to the global disease burden. T2D is already a major health threat in populations in developed countries and is rapidly taking hold in the…
- Trial name
- NCT00837122
- Where
- 5 sites in Ghana, Nigeria
- Volunteers
- 7,418 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Older Adults (50-90 Years), Depression
Integrating Depression Care Into HIV Services for Older People With HIV Using a Stepped Care, Task-Sharing Approach.
Depression levels will be compared using PHQ-9 in the Treatment as Usual arm(TAU) VS intervention arm to see if the stepped care intervention is effective in treating depression.
- Trial name
- NCT06894680
- Testing
- Stepped care, Treatment as usual
- Where
- Nigeria
- Volunteers
- 100 people
- Sponsor
- Royal Society of Tropical Medicine and Hygiene
Sickle Cell Disease
Hydroxyurea Optimisation in Sickle Cell Disease
The wide interindividual variability in clinical response to hydroxyurea therapy in the management of sickle cell disease has limited its use.
- Trial name
- PHOENIX-NG (NCT07543289)
- Testing
- Hydroxyurea (HU)
- Where
- Nigeria
- Volunteers
- 100 people
- Sponsor
- Ochuko Orherhe
Sensorineural Hearing Loss, Hearing Disorder
Genetic Analysis of Hereditary Disorders of Hearing and Balance
This study will try to identify the genetic causes of hereditary hearing loss or balance disorders. People with a hearing or balance disorder that affects more than one family member may be eligible for this study.
- Conditions
- Sensorineural Hearing Loss, Hearing Disorder, Vestibular Disease
- Trial name
- NCT00023049
- Where
- 2 sites in United States, Nigeria
- Volunteers
- 335 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Sickle Cell Disease
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to…
- Trial name
- NCT05031780
- Testing
- Mitapivat
- Where
- 91 sites in United States, Belgium and 14 more
- Volunteers
- 286 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Proteinuric Kidney Disease
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
- Trial name
- AMPLITUDE (NCT05312879)
- Testing
- VX-147
- Where
- 314 sites in United States, Belgium and 11 more
- Volunteers
- 522 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Lassa Fever
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
- Trial name
- NCT05868733
- Testing
- Day 1 Dose (2×106 pfu), Day 1 Dose (1×107 pfu), Day 1 Dose (2×10^5 pfu)
- Where
- 3 sites in Ghana, Liberia and 1 more
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Incentives
Evaluating the Impact of Demand-Side Incentives (DSI) on Zero Dose Burden and Immunisation Coverage in Nigeria
The goal of this cluster Randomised Controlled Trial (cRCT) is to evaluate the impact and effectiveness of demand-side incentives (DSIs) in improving immunisation coverage and reducing the burden of zero-dose children between the…
- Trial name
- NCT06676787
- Testing
- Transportation Voucher, Comunity engagement and microplannnig support, Direct Facility Funding, Community Engagement, and Microplaning Support, Transportation Voucher, Direct Facility Funding, Community engagement and Microplanning support
- Where
- 2 sites in Nigeria
- Volunteers
- 115,589 people, healthy volunteers welcome
- Sponsor
- Corona Management Systems
Breast Cancer, Breast Cancer Female
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
The purpose of this study is to train Nigerian radiologists to perform ultrasound-guided breast biopsies. Researchers will use mHealth devices to create a sustainable and practical way of training radiologists in Nigeria to…
- Trial name
- NCT05561842
- Testing
- mHealth US-breast biopsy
- Where
- 8 sites in United States, Nigeria
- Volunteers
- 900 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diabete Mellitus
Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary…
- Trial name
- HTN2 (NCT07589387)
- Testing
- Implementation of program based on WHO HEARTS-D guidelines, Metformin, Glimepiride
- Where
- 10 sites in Nigeria
- Volunteers
- 2,800 people
- Sponsor
- Washington University School of Medicine
HIV
Combination Intervention to Enhance Treatment Engagement and Viral Suppression Among Sexual and Gender Minority Youth in Nigeria
The study will adapt and test a combination peer navigation and mHealth approach, Intensive Combination Approach to Rollback the Epidemic in Nigeria (iCARE Nigeria), to improve HIV treatment engagement, medication adherence and…
- Trial name
- NCT06190613
- Testing
- Combination Peer navigation and mHealth intervention
- Where
- Nigeria
- Volunteers
- 110 people
- Sponsor
- Northwestern University
Chronic Myeloid Leukemia (CML)
Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy
Chronic myeloid leukaemia (CML) is a blood cancer with an annual worldwide incidence of 1/100,000 population. Imatinib is used for the treatment of CML and has significantly improved the management of the disease.
- Trial name
- NCT07022743
- Testing
- Imatinib, Artesunate
- Where
- Nigeria
- Volunteers
- 75 people
- Sponsor
- Obafemi Awolowo University
Hypertension (HTN)
Hypertension Treatment in Nigeria 2.0
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary…
- Trial name
- HTN 2 (NCT07351162)
- Testing
- Implementation of a modified WHO HEARTS Hypertension Treatment Bundle
- Where
- 49 sites in Nigeria
- Volunteers
- 10,000 people
- Sponsor
- Washington University School of Medicine
Chronic Lung Diseases
Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasE
This observational, multicentric prospective study aims to understand the prevalence and burden of antimicrobial resistance (AMR) in people with chronic lung diseases (CLD) across the globe, understanding also geographical…
- Trial name
- PRESIDE (NCT07874139)
- Where
- 68 sites in United States, Albania and 31 more
- Volunteers
- 683 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Covid19, Hiv
Effects of COVID-19 on Endothelium in HIV-Positive Patients in Sub-Saharan Africa
Background: Coronavirus disease 2019 (COVID-19) has affected almost every country in the world, especially in terms of health system capacity and economic burden.
- Conditions
- Covid19, Hiv, ART
- Trial name
- ENDOCOVID (NCT04709302)
- Testing
- COVID-19, HIV, ART
- Where
- 3 sites in Nigeria, South Africa
- Volunteers
- 342 people
- Sponsor
- Medical University of Graz
Post-mastectomy Pain Syndrome, Breast Cancer
Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
Phase III, international multicentre, parallel group, blinded, 1:1 randomized controlled trial to determine the effect of an intraoperative intravenous lidocaine infusion on reducing the development of persistent pain 3-months…
- Conditions
- Post-mastectomy Pain Syndrome, Breast Cancer, Pain, Postoperative, Pain, Chronic
- Trial name
- NCT04874038
- Testing
- Lidocaine 20mg/ml
- Where
- 17 sites in Canada, Nepal and 1 more
- Volunteers
- 1,604 people
- Sponsor
- University Health Network, Toronto
COVID-19
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication.
- Trial name
- NCT05605093
- Testing
- Shionogi Protease Inhibitor (S-217622)
- Where
- 187 sites in United States, Argentina and 22 more
- Volunteers
- 602 people
- Sponsor
- University of Minnesota
Sickle Cell Disease
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
The purpose of this study is to evaluate the pharmacokinetics and safety of etavopivat in paediatric participants with sickle cell disease (SCD).
- Trial name
- HIBISCUS KIDS (NCT06198712)
- Testing
- Etavopivat
- Where
- 18 sites in Canada, France and 5 more
- Volunteers
- 95 people
- Sponsor
- Forma Therapeutics, Inc.
Sickle Cell Disease, Thalassemia
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin.
- Trial name
- FLORAL (NCT06609226)
- Testing
- Etavopivat A, Etavopivat B, Etavopivat C
- Where
- 107 sites in United States, Canada and 15 more
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Diabetes
BGM and HbA1c POC Device Evaluation
This study aims to assess analytical performance of four BGMs and four HbA1c POC devices in comparison to suitable comparator or reference methods, with the view to evaluate performance in the hands of trained users, as well as…
- Trial name
- NCT06170515
- Testing
- CareSens N-Eco (i-Sens), • CareSens N-Premier (i-Sens), CodeFree (SD Biosensor), GlucoNavii GDH (SD Biosensor), Affinion (Abbott), HbA1c 501 (HemoCue), A1Care (iSens), DCA Vantage (Siemens)
- Where
- 3 sites in Cambodia, Colombia and 1 more
- Volunteers
- 910 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland